Galderma Announces Unprecedented Growth in Dermatological Skincare and Injectables

Galderma reported record net sales of $2.448 billion for the first half of 2025, a 12% increase year-on-year. The rise involved contributions from all three business categories: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology.

Derma Skincare Growth

• Cetaphil and Alastin: The Derma Skincare division grew by 7.7%, driven by exceptional performance in Asia, with India as a top contributor.
• In the US, Cetaphil saw growth across e-commerce and major retailers, while Alastin maintained double-digit growth.
• Growth was supported by new products like Cetaphil’s Acne Fast Rescue Pimple Patches and Alastin’s Restorative Skin Complex.

Marketing and Partnerships

• CetaSphere Network: A global advocacy network and a successful Cetaphil campaign in China boosted sales, especially during the “618” shopping festival.
• Alastin Visibility: Collaborations with Halle Berry at high-profile events increased brand visibility.
• Retail and E-commerce Strategy: Strong retailer engagement and growing e-commerce channels contributed to sales.

Other Growth Areas

• Injectable Aesthetics and Therapeutic Dermatology: New product launches like Relfydess contributed to growth.
• Consumer Demand: Interest in aesthetic procedures and science-based skincare supported sales.
• Innovation in GLP-receptor Drugs: Addressing side effects like aged appearance from drugs such as Ozempic.

US Expansion

• New Miami HQ: Galderma established a new headquarters in Miami to drive innovation and growth in the U.S. market, focusing on Dermatological Skincare and Injectable Aesthetics.
• CEO Flemming Ørnskov emphasized the company’s aim to become a leading powerhouse in dermatology.